Seagen (SGEN) PT Lowered to $146 at Wolfe Research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Seagen (SGEN) Stock Plunges on Weak Outlook and Q4 Miss, Analysts Lower Price Targets
February 10, 2022 7:14 AM ESTShares of Seagen (NASDAQ: SGEN) plummeted more than 16.5% in premarket trading on Thursday after the biotech company reported Q4 2021 and FY 2021 financial results.
The company reported that Q4 revenue climbed to $369.2 million, down from $601.3 million in the year-ago period. FY 2021 revenue came in at $1.57 billion, way below $2.17 billion reported in Q4 2020. Analysts were calling for Q4 EPS of ($0.82) on sales of $406.87 million.
Seagen sees 2022 revenue of $1.48-1.545 billion, versus the consensus of $2.16 billion.
Total net product... More
Seagen (SGEN) PT Lowered to $170 at H.C. Wainwright
February 10, 2022 6:40 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Seagen (NASDAQ: SGEN) to $170.00 (from $200.00) while maintaining a Buy rating following results.
The analyst commented, "Yesterday, Seagen delivered revenue guidance which fell below consensus estimates suggestive of incremental to flat sales growth... More
